trial

Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia

NCTId NCT00103727
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 282 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2005-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
282 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-12
Primary completion
2005-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
TalnetantRisperidone

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

22 total
Little Rock, United StatesAnaheim, United StatesCerritos, United StatesGarden Grove, United StatesGlendale, United StatesNational City, United StatesOceanside, United StatesPico Rivera, United StatesRosemead, United StatesSan Diego, United StatesSan Diego, United StatesUpland, United States

Linked catalysts

1
Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia — primary completion2005-10

Facts & assertions

4 sourced
Enrollment
282
Phase
PHASE2
Primary Completion Date
2005-10
Status
COMPLETED
relationships
The graph out of here
drug
Talnetant
drug
Risperidone
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication
Catatonia
indication